Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies

Bristol-Myers Squibb

Summary

Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.

Eligibility

Age range: 18+ years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria * Signed Written Informed Consent. * Eligible to receive continued study treatment per the Parent Study, including treatment beyond progression per investigator assessment in the Parent Study. * On treatment hold in the Parent Study following long-lasting response or are eligible for treatment rechallenge as defined in the Parent Study. * WOCBP and male participants who are sexually active must agree to follow instructions for method(s) of contraception as described below and included in the ICF. Exclusion Criteria * Participant is not eligible for study treatment per the…

Interventions

Drug
Nivolumab
Specified dose on specified days
Drug
Ipilimumab
Specified dose on specified days
Drug
Cabozantinib
Specified dose on specified days
Drug
Trametinib
Specified dose on specified days
Drug
Relatlimab
Specified dose on specified days
Drug
Nivolumab + Relatlimab
Specified dose on specified days
Drug
Capecitabine
Specified dose on specified days
Drug
Bevacizumab
Specified dose on specified days
Drug
Temozolomide
Specified dose on specified days
Drug
Rucaparib
Specified dose on specified days
Drug
Daratumumab
Specified dose on specified days
Drug
Regorafinib
Specified dose on specified days
Drug
Leucovorin
Specified dose on specified days
Drug
Fluorouracil
Specified dose on specified days
Drug
Oxaliplatin
Specified dose on specified days
Drug
Enzalutamide
Specified dose on specified days
Drug
Sunitinib
Specified dose on specified days
Drug
Pemetrexed
Specified dose on specified days
Drug
Pembrolizumab
Specified dose on specified days

Summary

Eligibility

Interventions

Locations (399)